about
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society.New worldwide lipid guidelines.PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study.What imaging techniques should be used in primary versus secondary prevention for further risk stratification?Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era.Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal.Optimizing Cholesterol Treatment in Patients With Muscle Complaints.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.Prediction of cardiovascular risk in patients with familial hypercholesterolaemia.Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland CoroLegacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe.Inclisiran for the treatment of dyslipidemia.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.Diabetic microvascular triopathy, smoking, and risk of cardiovascular events - Author's reply.Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study).Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1Epidemiology of familial hypercholesterolaemia: Community and clinicalImproving the global care of familial hypercholesterolaemia: Starting the ball rollingFeasibility Study Protocol: The Use of American Heart Association�s Cholesterol CarePlan to be Delivered as a Web Application on a Smartphone to Patients Prescribed Cholesterol Lowering Medication (Preprint)Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab TrialsEthnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality riskBenefits of achieving the NCEP optional LDL-C goal among elderly patients with ACSLipids and Lipoproteins in Risk PredictionResponse by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trialsWill genetic studies deliver the next generation of cardioprotective therapies?The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes
P50
Q30364133-43E6C497-A72D-4DDD-8270-F6BDBABF2B61Q36663511-F51780E5-7E53-45BD-9ABA-CADD9721607DQ37177894-6B65DAF5-3A74-4917-9B99-2A3D41D0352DQ37654298-2E3122D8-6004-47DE-BF95-BC1EDE09C853Q38255556-3DE25795-93A9-4964-A74D-82EC0D31FBA9Q38518117-D91D1ED8-FAA3-49BC-A9A5-A2899970AA19Q38735377-D378C2FA-FEDD-43CE-9C52-C91C74C78DEEQ38791017-74E42FE9-55D4-40C3-A4A6-0B6F543B751BQ38824414-EDFD4A5C-3367-4923-9703-10BCEA0207D7Q38901200-49C282AD-9BF9-4722-B878-50E881A98EC8Q39013114-62D07C4A-AC95-4474-93F0-C051EA41C601Q39341640-BCBCBAE0-E81B-4A07-A726-B2C4D624C723Q39401231-5F7B601C-0A61-4103-AA73-3055770BD20DQ40062527-2304F240-241A-4BCC-9FAA-A2EACE6DEF16Q44847105-42ECD9B4-E0D9-4F00-9962-98E384494D9DQ45974771-CC0688AF-4112-46DA-97AE-D39A79BDDAEDQ47643635-A84D004C-E477-4058-9754-74259708DC09Q47846997-0B74B87E-67F1-41A2-8D32-DF07C211CD57Q48099286-4164355D-647D-409A-A913-1E6963A66C4EQ48570562-F6326AD6-20E5-4C1E-9BF6-1152524F011AQ49507534-742A1DBF-C195-4860-8406-99A0AAC33262Q49935235-244A9467-E0C0-4893-9E29-8371C008FA8FQ50047295-024DF334-682A-41F2-AB91-56D9A692419FQ50129514-DF8BA1F3-3C3C-4EC0-AFD5-7734F4208D72Q51056145-7050317F-4501-4962-A893-21154FDC2898Q51096176-E5394DBC-6E64-4DA2-9CC8-3AD975535F45Q52603877-C763C5F5-DF47-4859-9695-853E0D473807Q52606509-544507D7-6FF2-4EE2-8D15-B386747195DAQ56968784-DEEAE103-37E6-4E42-AC37-3DAA269B9011Q57052367-764A45C0-A1E4-4F33-B45F-980D46CD219DQ57052386-85F6F8A2-3A2E-4C61-8613-3B31009A241CQ57317395-E3FBE745-37FA-4164-AB36-897B5CFC5C05Q58127079-20731248-9188-49E3-A1F5-8F6E705300F1Q58961325-5C8478D2-6581-48AC-929E-7DF3B1F3AD67Q80057720-BCF8E2D9-DA5C-4118-B05A-0033C169C5D4Q88247324-B58D6F67-06BF-4AC3-93D0-8473D1FFA25FQ88909530-799B0021-A8A4-4A14-8F47-E0A522CE9FC9Q89052015-A8A8C512-AC62-46EB-B7BA-2796EDBD75DAQ89902232-BEF5BA89-7AB6-43E3-B8CF-6785AF4AC702Q90012664-3A2591D4-EEE8-4D80-A984-E40900C48F8C
P50
description
investigador
@es
researcher
@en
name
Kausik K Ray
@en
Kausik K Ray
@nl
type
label
Kausik K Ray
@en
Kausik K Ray
@nl
prefLabel
Kausik K Ray
@en
Kausik K Ray
@nl
P31
P496
0000-0002-7166-060X